2024 Seattle Cellular Therapy Summit: Updates and Focus on Accessibility

Seattle, WA US
August 16, 2024 to August 17, 2024

This CME-accredited activity, “2024 Seattle Cellular Therapy Summit: Updates and Focus on Accessibility” features leading experts in hematologic malignancies and cellular therapies who will provide a comprehensive overview of current and emerging strategies for the management of lymphoma, myeloma, acute leukemias, and solid tumors with a focus in the use of cellular therapies. The goal of this activity is to improve the knowledge and competence of learners to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients with hematologic malignancies and to describe potential future applications of cellular therapy in solid tumors. The activity will use a mix of didactic lectures and case-based discussions to highlight areas of debate between cellular therapy and non-cellular therapy in the treatment of these diseases. Expert faculty will aim to place the role of different therapeutic agents in a clinical context and discuss how to utilize these therapeutic options to effectively contribute to patient care. This conference is designed to provide physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals with the latest updates in the field. It will highlight a multidisciplinary approach and the integration of new advances in patient-centered care.

The symposium will augment healthcare providers’ foundation of knowledge and clinical competence in several areas:

  • Providing a review of existing clinical evidence supporting approved Chimeric Antigen Receptor T-cell (CAR T) therapies in the care of patients with B-cell Acute Lymphoblastic Leukemia (B-ALL), Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), and Multiple Myeloma (MM)
  • Describing the role of non-cellular therapies in B-ALL, DLBCL, FL, MCL, and MM
  • Identify challenges to the delivery of cellular therapies and provide a discussion on how such barriers may be addressed
  • Discussing novel investigational approaches of cellular therapy in acute myeloid leukemias and solid tumors

Organizing Committee

Conference Director: 

Binay Shah, MD, MHA - Binaytara Foundation

Conference Co-Chairs:

Mazyar Shadman, MD, MPH - Fred Hutchinson Cancer Center and the University of Washington

Krish Patel, MD - Swedish Cancer Institute

Target Audience

  • Hematologists/Medical Oncologists 
  • Oncology fellows
  • Oncology nurses
  • NPs/PAs
  • Oncology pharmacists

Hotel Information

If you are attending this meeting and need to reserve a hotel room, please reserve your room at the link below to take advantage of the discounted group rate of $263 per night plus applicable taxes and fees:

 https://www.marriott.com/event-reservations/reservation-link.mi?id=1699985736187&key=GRP&app=resvlink

The deadline to reserve the hotel room is Thursday, July 25, 2024.

 

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  • Review indications and outcomes of approved cellular therapies in hematologic malignancies
  • Identify emerging CAR-based therapies in hematologic malignancies and solid tumors
  • Identify and manage complications after cellular therapy
  • Incorporate into practice knowledge about financial toxicity and quality of life after CAR T-cell therapies
  • State the financial, physical, and other barriers, review strategies to navigate these factors to optimize the management of patients with cellular therapies

GLOBAL ONCOLOGY PROJECT

Click this link to learn more about our ongoing project building a 200-bed cancer hospital in Nepal: https://binayfoundation.org/cancer-hospital/

Course summary
Course opens: 
10/16/2023
Course expires: 
11/16/2024
Event starts: 
08/16/2024 - 8:00am PDT
Event ends: 
08/17/2024 - 4:15pm PDT
Cost:
$300.00
Add to calendar: 

DAY 1 – Friday, August 16, 2024

All times are listed in Pacific Standard Time (PST)

07:00 AM – 08:00 AM: REGISTRATION, EXHIBITS, & SOCIALIZE

08:00 AM - 08:05 AM: Welcome

08:05 AM – 09:15 AM: SESSION 1: Updates on Approved CAR-T Therapies

Chairs: Mazyar Shadman, MD

08:05 AM – 08:15 AM: Updates in CAR-T therapy for lymphoma - Alan Skarbnik, MD

08:15 AM – 08:30 AM: Updates in CAR-T therapy for Myeloma - 

08:30 AM– 08:45 AM: Updates in CAR-T therapy for Leukemia - 

08:45 AM – 09:15 AM: Panel Discussion

09:15 AM – 09:30 AM: BREAKS & EXHIBITS

09:30 AM – 11:00 AM: SESSION 2: Immunotherapy for Solid tumors

Chairs: Kelly Paulson, MD

09:30 AM – 09:45 AM: Immunotherapy for Solid Tumors- Future direction - Lawrence Fong, MD

09:45 AM – 10:00 AM: TIL Therapy for Melanoma - Kelly Paulson, MD

10:00 AM – 10:15 AM: TCR therapy for Sarcoma - 

10:15 AM – 10:30 AM: Cellular immunotherapy for gynecologic malignancies - Fernanda Musa, MD

10:30 AM – 10:45 AM: Cellular immunotherapy for breast cancer - Jennifer Specht, MD

10:45 AM – 11:00 AM: Panel Discussion

11:00 AM – 11:45 AM: NON-CME ACTIVITY

11:45 AM – 12:45 PM: LUNCH & EXHIBITS

12:45 PM – 01:45 PM: SESSION 3: Complications

Chairs: Mazyar Shadman, MD & Krish Patel, MD

12:45 PM – 01:00 PM: Advances in prevention and management of CRS and ICANS - 

01:00 PM – 01:15 PM: Prevention and treatment of infectious complications after CAR-T therapy - Joshua Hill, MD

01:15 PM– 01:30 PM: Second malignancies after CAR-T therapy - Alexandre Hirayama, MD

01:30 PM – 01:45 PM: CAR-T therapy for autoimmune diseases - Krish Patel, MD

01:45 PM – 02:00 PM: BREAK & EXHIBITS

02:00 PM – 02:45 PM: SESSION 4: Access to Cellular Immunotherapy

Chairs: Krish Patel, MD

02:00 PM – 02:15 PM: Cellular immunotherapy in the outpatient setting - Aravind Ramakrishnan, MD

02:15 PM – 02:30 PM: Improving access to CAR-T therapy - Marc Hoffman, MD

02:30 PM – 02:45 PM: Panel Discussion - Krish Patel, MD; Lisa Getzendaner, PA-C, MHS

DAY 2 – Saturday,  August 17, 2024

07:00 AM – 08:00 AM: REGISTRATION, EXHIBITS, & NETWORKING

07:30 AM – 08:00 AM: Meet the Experts - Thomas Martin, MD

08:00 AM – 08:15 AM: Binaytara Foundation's Efforts in Improving Cancer Care Disparities - Binay Shah, MD

08:15 AM – 10:35 AM: SESSION 5: Debates in Myeloma

Chairs: Rahul Banerjee, MD & Swathi Namburi, MD

What is the right sequence of immunotherapy in multiple myeloma?

08:15 AM – 08:20 AM: Case Presentation

08:20 AM – 08:30 AM: Bispecific antibodies before CAR-T therapy - Meera Mohan, MD, MS, FACP

08:30 AM – 08:40 AM: CAR-T therapy before bispecific antibodies

What is the best second line treatment option for myeloma?

08:40 AM – 08:45 AM: Case Presentation

08:45 AM – 08:55 AM: Favor CAR-T therapy for second line - Gurbakhash Kaur, MD

08:55 AM – 09:05 AM: Favor non CAR-T options for second line

Is immunotherapy an option for Smoldering myeloma?

09:05 AM – 09:10 AM: Case Presentation

09:10 AM – 09:20 AM: Favor immunotherapy for smoldering myeloma - Yuxin Liu, MD

09:20 AM – 09:30 AM: Favor conventional (non-immunotherapy) for smoldering myeloma - Andrew Cowan, MD

09:30 AM – 09:40 AM: Favor no intervention for smoldering myeloma - Samuel Rubinstein, MD

09:40 AM – 09:50 AM: Novel target CAR-T - Swathi Namburi, MD

09:50 AM – 10:35 AM: Panel Discussion

10:35 AM – 11:50 AM: SESSION 6: Debates in Lymphoma Part 1

Chairs: 

Should anti-CD19 therapies be used before CD19 targeted Car-T therapy?

10:35 AM – 10:40 AM: Case Presentation

10:40 AM – 10:50 AM: YES - Mehdi Hamadani, MD

10:50 AM – 11:00 AM: NO - Matthew Lunning, DO 

What is the best treatment option for post CD19 CAR-T?

11:00 AM – 11:05 AM: Case Presentation

11:05 AM – 11:15 AM: Bispecific antibodies - Tycel Phillips, MD

11:15 AM – 11:25 AM: Other cellular therapy options - Matthew Frank, MD, PhD

Immunotherapy for first line DLBCL

11:25 AM – 11:30 AM: Case Presentation

11:30 AM – 11:40 AM: CAR-T as the best immunotherapy option for first line

11:40 AM – 11:50 AM: Bispecific antibodies as best first-line option for first line - Ryan Lynch, MD

11:50 AM – 12:50 PM: LUNCH, EXHIBITS

12:50 PM – 02:50 PM SESSION 6: Debates in Lymphoma Part 2

Bispecific antibodies or CAR-T for relapsed FL

12:50 PM – 12:55 PM: Case Presentation

12:55 PM – 01:05 PM: Favor CAR-T:

01:05 PM – 01:15 PM: Favor bispecific antibodies: Elizabeth Budde, MD, PhD

With Liso-cel approval, which CAR-T product is preferred for MCL?

01:15 PM – 01:20 PM: Case Presentation

01:20 PM – 01:30 PM: Brexu-cel - Michael Jain, MD, PhD

01:30 PM – 01:40 PM: Liso-cel

Which immunotherapy option is more promising for T-cell lymphoma?

01:40 PM – 01:45 PM: Case Presentation

01:45 PM – 01:55 PM: CAR-T: Rayne Rouce, MD

01:55 PM – 02:05 PM: Antibody-based immunotherapy - Christina Poh, MD

02:05 PM – 02:50 PM: Panel Discussion

02:50 PM – 03:05 PM: BREAKS & EXHIBITS

03:05 PM – 04:45 PM: SESSION 7: Debates in Leukemia

Chairs: Filippo Milano, MD, PhD

03:05 PM – 03:20 PM: Current state of cellular immunotherapy for AML - Naval Daver, MD

CAR-T Therapy of choice for ALL

03:20 PM – 03:25 PM: Case presentation

03:25 PM – 03:35 PM: Brexu-cel - 

03:35 PM – 03:45 PM: Obe-cel - Nitin Jain, MD

Treatment strategy for CLL patients with “double refractory” disease

03:45 PM – 03:50 PM: Case presentation

03:50 PM – 04:00 PM: CAR-T (liso-cel) - Nirav Shah, MD

04:00 PM – 04:10 PM: Pirtobrutinib - Catherine Coombs, MD

04:10 PM – 04:20 PM: Allogeneic stem cell transplant - Mazyar Shadman, MD

The most promising immunotherapy option for Richter Transformation

04:20 PM – 04:25 PM: Case presentation

04:25 PM – 04:35 PM: CAR-T - Adam Kittai, MD

04:35 PM – 04:45 PM: Bispecific antibodies

04:45 PM: ADJOURN

The Westin Seattle
1900 5th Ave
Seattle, WA 98101
United States

If you are attending this meeting and need to reserve a hotel room, please reserve your room at the link below to take advantage of the discounted group rate of $263 per night plus applicable taxes and fees:

https://www.marriott.com/event-reservations/reservation-link.mi?id=1699985736187&key=GRP&app=resvlink

The deadline to reserve the hotel room is Thursday, July 25, 2024.

FACULTY INFORMATION COMING SOON

 

Course Director(s)

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.
Conference Chair(s)

Krish Patel, MD

has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with Pfizer;.
has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Professional Services) with BeiGene;.
has a financial relationship (Professional Services) with Fate Therapeutics;.
has a financial relationship (Professional Services) with Lilly;.
has a financial relationship (Professional Services) with Sana;.
has a financial relationship (Professional Services) with Abbvie;.
has a financial relationship (Professional Services) with Epizyme;.
has a financial relationship (Professional Services) with Janssen/Pharmacyclics;.
has a financial relationship (Professional Services) with Xencor;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Caribou;.
has a financial relationship (Professional Services) with Kite;.
has a financial relationship (Professional Services) with ADC Therapeutics;.

Mazyar Shadman, MD,MPH

has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Vincerx ;.
has a financial relationship (Professional Services) with Eli Lily ;.
has a financial relationship (Professional Services) with Mustang Bio ;.
has a financial relationship (Professional Services) with BeiGene;.
has a financial relationship (Employment) with BMS;.
has a financial relationship (Professional Services) with Kite Pharma ;.
has a financial relationship (Professional Services) with Nurix;.
has a financial relationship (Professional Services) with AbbVie;.
has a financial relationship (Professional Services) with MorphoSys/Incyte;.
has a financial relationship (Professional Services) with Janssen ;.
has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with Genmab;.
has a financial relationship (Stock Options) with Koi Biotherapeutics;.
has a financial relationship (Professional Services) with Fate therapeutics;.
Session Chair(s)

Rahul Banerjee, MD, FACP

has a financial relationship (Grant Or Contract) with i3 Health;.
has a financial relationship (Independent contractor) with Clearview Healthcare Partners;.
has a financial relationship (Independent contractor) with BMS;.
has a financial relationship (Grant Or Contract) with Clinical Care Options;.
has a financial relationship (Independent contractor) with Guidepoint Global;.
has a financial relationship (Grant Or Contract) with Pack Health;.
has a financial relationship (Grant Or Contract) with Curio Science;.
has a financial relationship (Independent contractor) with Sanofi Pasteur;.
has a financial relationship (Independent contractor) with Janssen Oncology;.
has a financial relationship (Independent contractor) with SparkCures;.
has a financial relationship (Independent contractor) with Genentech/Roche;.

Filippo Milano

has no relevant financial relationships to disclose at this time.
Speaker/Topic Presenter(s)

Lihua Budde, M.D., Ph.D.

has a financial relationship (Financial Support) with ADC Therapeutics;.
has a financial relationship (Grant Or Contract) with Amgen;.
has a financial relationship (Financial Support) with AstraZeneca;.
has a financial relationship (Grant Or Contract) with AstraZeneca;.
has a financial relationship (Financial Support) with Roche;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Financial Support) with Genentech;.
has a financial relationship (Financial Support) with Janssen;.

Catherine Coombs

has a financial relationship (Independent contractor) with Beigene;.
has a financial relationship (Independent contractor) with Allogene;.
has a financial relationship (Independent contractor) with Octapharma;.
has a financial relationship (Independent contractor) with Genentech;.
has a financial relationship (Independent contractor) with Janssen;.
has a financial relationship (Independent contractor) with MEI Pharma;.
has a financial relationship (Independent contractor) with AbbVie;.
has a financial relationship (Independent contractor) with Lilly;.
has a financial relationship (Independent contractor) with TG therapeutics;.
has a financial relationship (Independent contractor) with AstraZeneca;.
has a financial relationship (Independent contractor) with Mingsight;.

Andrew Cowan, MD

has a financial relationship (Independent contractor) with Harpoon;.
has a financial relationship (Professional Services) with Sanofi;.
has a financial relationship (Independent contractor) with Adaptive Biotechnology;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Independent contractor) with Sanofi;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Independent contractor) with Janssen;.
has a financial relationship (Independent contractor) with Nektar;.
has a financial relationship (Professional Services) with Adaptive Biotech;.
has a financial relationship (Independent contractor) with Abbvie;.

Matthew Frank, MD PhD

has a financial relationship (Travel) with Cargo Therapeutics;.
has a financial relationship (Grant Or Contract) with Cargo Therapeutics;.
has a financial relationship (Travel) with Kite Pharma-Gilead;.
has a financial relationship (Grant Or Contract) with Adaptive Biotechnology;.
has a financial relationship (Grant Or Contract) with Kite Pharma-Gilead;.
has a financial relationship (Grant Or Contract) with Allogene Therapeutics;.

Mehdi Hamadani

has a financial relationship (Other) with ADC Therapeutics, AstraZeneca, Bei Gene, Kite. ;.
has a financial relationship (Professional Services) with ADC Therapeutics, Omeros, CRISPR, BMS, Kite, AbbVie, Caribou, Genmab. ;.

Marc Hoffmann, Associate Professor; Director, Lymphoma Program

has a financial relationship (Independent contractor) with ADC Therapeutics;.
has a financial relationship (Independent contractor) with Novartis;.
has a financial relationship (Independent contractor) with AbbVie;.
has a financial relationship (Independent contractor) with Astra-Zeneca;.
has a financial relationship (Independent contractor) with Genentech;.
has a financial relationship (Independent contractor) with BeiGene;.
has a financial relationship (Independent contractor) with Janssen;.

Michael Jain

has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with Kite/Gilead;.
has a financial relationship (Professional Services) with Myeloid Therapeutics;.

Adam Kittai, MD

has a financial relationship (Grant Or Contract) with BeiGene;.
has a financial relationship (Grant Or Contract) with AstraZeneca;.
has a financial relationship (Independent contractor) with BMS;.
has a financial relationship (Independent contractor) with BeiGene;.
has a financial relationship (Independent contractor) with AstraZeneca;.

Ryan Lynch

has a financial relationship (Other) with Janssen;.
has a financial relationship (Grant Or Contract) with RAPT;.
has a financial relationship (Grant Or Contract) with SeaGen;.
has a financial relationship (Grant Or Contract) with TG Therapeutics;.
has a financial relationship (Grant Or Contract) with Genentech;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Grant Or Contract) with Bayer;.
has a financial relationship (Grant Or Contract) with Cyteir;.
has a financial relationship (Other) with Merck;.
has a financial relationship (Grant Or Contract) with Janssen;.
has a financial relationship (Grant Or Contract) with Incyte;.
has a financial relationship (Other) with Seagen;.

Krish Patel, MD

has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with Pfizer;.
has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Professional Services) with BeiGene;.
has a financial relationship (Professional Services) with Fate Therapeutics;.
has a financial relationship (Professional Services) with Lilly;.
has a financial relationship (Professional Services) with Sana;.
has a financial relationship (Professional Services) with Abbvie;.
has a financial relationship (Professional Services) with Epizyme;.
has a financial relationship (Professional Services) with Janssen/Pharmacyclics;.
has a financial relationship (Professional Services) with Xencor;.
has a financial relationship (Professional Services) with Caribou;.
has a financial relationship (Professional Services) with Kite;.
has a financial relationship (Professional Services) with ADC Therapeutics;.
has a financial relationship (Professional Services) with AstraZeneca;.

Christina Poh, MD

has a financial relationship (Other) with Astex;.
has a financial relationship (Other) with Ipsen;.
has a financial relationship (Other) with Seagen;.
has a financial relationship (Other) with Acrotech;.
has a financial relationship (Other) with Dren Bio;.

Samuel Rubinstein

has a financial relationship (Independent contractor) with Janssen;.
has a financial relationship (Independent contractor) with LAVA Therapeutics;.
has a financial relationship (Independent contractor) with Sanofi;.

Mazyar Shadman, MD,MPH

has a financial relationship (Professional Services) with BeiGene;.
has a financial relationship (Employment) with BMS;.
has a financial relationship (Professional Services) with Kite Pharma ;.
has a financial relationship (Professional Services) with Nurix;.
has a financial relationship (Professional Services) with Mustang Bio ;.
has a financial relationship (Professional Services) with MorphoSys/Incyte;.
has a financial relationship (Professional Services) with Janssen ;.
has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Professional Services) with AbbVie;.
has a financial relationship (Professional Services) with Genmab;.
has a financial relationship (Stock Options) with Koi Biotherapeutics;.
has a financial relationship (Professional Services) with Fate therapeutics;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Vincerx ;.
has a financial relationship (Professional Services) with Eli Lily ;.
has a financial relationship (Professional Services) with BMS;.

Alan Skarbnik, MD

has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Kite Pharma;.
has a financial relationship (Professional Services) with GenMab;.
has a financial relationship (Professional Services) with ADC Therapeutics;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with Pharmacyclics;.
has a financial relationship (Professional Services) with Abbvie;.
has a financial relationship (Professional Services) with Beigene;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Celgene;.
has a financial relationship (Professional Services) with Lilly;.

Jennifer Specht, MD

has a financial relationship (Professional Services) with GE Healthcare;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Grant Or Contract) with Abbvie ;.
has a financial relationship (Grant Or Contract) with AstraZeneca;.
has a financial relationship (Other) with A2 Biotherapeutics ;.
has a financial relationship (Grant Or Contract) with Seattle Genetics;.
has a financial relationship (Grant Or Contract) with Celcuity;.
has a financial relationship (Grant Or Contract) with Carisma Therapeutics;.
has a financial relationship (Professional Services) with Volastra Therapeutics;.
has a financial relationship (Grant Or Contract) with Genentech;.
has a financial relationship (Grant Or Contract) with Lyell Immunopharma;.
has a financial relationship (Professional Services) with Sensei Biotherapeutics;.
has a financial relationship (Grant Or Contract) with Xencor;.
has a financial relationship (Professional Services) with Lyell Immunopharma Inc;.
Case Presenter(s)

Lisa Getzendaner, PA-C, MHS

has a financial relationship (Independent contractor) with Kite Pharmaceuticals;.

Thomas Martin, MD

has a financial relationship (Independent contractor) with GSK;.
has a financial relationship (Grant Or Contract) with Janssen;.
has a financial relationship (Grant Or Contract) with sanofi;.
has a financial relationship (Independent contractor) with Pfizer;.

If you are interested in exhibiting at this meeting, please email sponsorships@binayfoundation.org

 

Price

Cost:
$300.00
Please login or register to take this course.

REGISTRATION FEES 

Physicians (non-industry) - $300

Non-physician HCP (non-industry) - $200

Industry representatives - $1250

If your company has purchased an exhibit or sponsorship, please register at the link below to receive the discounted registration fees:

Link to register as an additional rep of a sponsoring company: https://education.binayfoundation.org/industry_registraiton_nocme .

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

Attend Only Registration Terms & Conditions:

Employees of companies that have not purchased an exhibit space or are not a sponsor of the conference should refrain from interacting with healthcare provider attendees outside of the main meeting room. This applies to ALL interactions except for asking content-relevant questions to faculty inside the meeting room where the CME-accredited activity occurs. Please do not engage in product promotion activity with any attendees or faculty of the conference. 

If your company has not purchased an exhibit space or sponsorship, and you engage in any promotional activity, including but not limited to introducing yourself to healthcare providers as an employee of the company, handing out business cards and product brochures/flyers, setting up visits/appointments, inviting them to promotional talks, etc., we will invoice YOU for the full cost of a premium exhibit table.

If your company has not purchased an exhibit space or sponsorship, please limit your interaction with healthcare providers attending this conference to "hello" only if you know the provider. Failure to comply with this requirement may result in being banned from all future conferences.

Employees of companies who are not exhibiting or sponsoring the conference may not enter the exhibit area. The exhibit area is ONLY for exhibitors and sponsors to engage in sales activity. Many of our conferences have meals in the exhibit hall; if the meal is in the exhibit hall, you will need to make alternative arrangements for your meals as you will not be provided meals by the meeting.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity which include registration, participation in the live activity, and completion of pre & post-tests as well as course evaluations.